JP2015522580A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522580A5
JP2015522580A5 JP2015519154A JP2015519154A JP2015522580A5 JP 2015522580 A5 JP2015522580 A5 JP 2015522580A5 JP 2015519154 A JP2015519154 A JP 2015519154A JP 2015519154 A JP2015519154 A JP 2015519154A JP 2015522580 A5 JP2015522580 A5 JP 2015522580A5
Authority
JP
Japan
Prior art keywords
epitope
polypeptide
composition
polypeptide antigen
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522580A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/063749 external-priority patent/WO2014005958A1/en
Publication of JP2015522580A publication Critical patent/JP2015522580A/ja
Publication of JP2015522580A5 publication Critical patent/JP2015522580A5/ja
Pending legal-status Critical Current

Links

JP2015519154A 2012-07-06 2013-06-29 免疫学的組成物およびその使用 Pending JP2015522580A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261669010P 2012-07-06 2012-07-06
US61/669,010 2012-07-06
US201261698971P 2012-09-10 2012-09-10
US61/698,971 2012-09-10
PCT/EP2013/063749 WO2014005958A1 (en) 2012-07-06 2013-06-29 Immunogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2015522580A JP2015522580A (ja) 2015-08-06
JP2015522580A5 true JP2015522580A5 (https=) 2016-08-18

Family

ID=48703552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519154A Pending JP2015522580A (ja) 2012-07-06 2013-06-29 免疫学的組成物およびその使用

Country Status (5)

Country Link
US (1) US20150140068A1 (https=)
EP (1) EP2869842A1 (https=)
JP (1) JP2015522580A (https=)
CN (1) CN104853770A (https=)
WO (1) WO2014005958A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
EA201792501A1 (ru) * 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
WO2016184822A1 (en) * 2015-05-15 2016-11-24 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
WO2017120577A1 (en) 2016-01-08 2017-07-13 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
EP3416978A4 (en) 2016-02-16 2019-11-06 Geovax, Inc. MULTIVALENT HIV VACCINE BOOST COMPOSITION AND METHOD OF USE
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
MX2020005584A (es) * 2017-12-04 2020-09-14 Intervet Int Bv Vacunacion con particulas de replicon y adyuvante oleoso.
EP3720489A1 (en) * 2017-12-04 2020-10-14 Intervet International B.V. Canine lyme disease vaccine
WO2019121513A1 (en) * 2017-12-18 2019-06-27 Intervet International B.V. Swine influenza a virus vaccine
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
CA3176481A1 (en) * 2020-04-22 2021-10-28 Marjoh NAUTA Coronavirus vaccine
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186745A (en) 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6054288A (en) 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
US5397307A (en) 1993-12-07 1995-03-14 Schneider (Usa) Inc. Drug delivery PTCA catheter and method for drug delivery
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
JP3403233B2 (ja) 1994-01-20 2003-05-06 テルモ株式会社 バルーンカテーテル
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
AU3876695A (en) 1994-11-17 1996-06-17 Imperial College Of Science, Technology And Medicine Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6090619A (en) 1997-09-08 2000-07-18 University Of Florida Materials and methods for intracellular delivery of biologically active molecules
US6129705A (en) 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
DE60044125D1 (de) * 1999-04-14 2010-05-20 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DK2311848T3 (da) 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
NZ606591A (en) * 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2015522580A5 (https=)
JP2014520807A5 (https=)
JP2014522842A5 (https=)
Zhao et al. Vaccine adjuvants: mechanisms and platforms
Brisse et al. Emerging concepts and technologies in vaccine development
O’Hagan et al. New generation adjuvants–from empiricism to rational design
Chen et al. Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy
JP6407208B2 (ja) 合成ナノキャリア混合ワクチン
Wilschut Influenza vaccines: the virosome concept
Huang et al. Research progress on emulsion vaccine adjuvants
García et al. An overview of adjuvant formulations and delivery systems
JP5654345B2 (ja) 多量体マルチエピトープインフルエンザワクチン
Goetz et al. Vaccine adjuvants for infectious disease in the clinic
Zurbriggen Immunostimulating reconstituted influenza virosomes
Dey et al. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens
CA2885741C (en) Vaccine comprising r-dotap
JP2018514565A5 (https=)
Hirschberg et al. A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus
Korsholm et al. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status
Cordeiro et al. Recent advances in vaccine delivery
Shen et al. Precise Epitope Organization with Self‐adjuvant Framework Nucleic Acid for Efficient COVID‐19 Peptide Vaccine Construction
Huckriede et al. Influenza virosomes in vaccine development
Liang et al. Nanoparticles in subunit vaccines: immunological foundations, categories, and applications
Krasnopolsky et al. Licensed liposomal vaccines and adjuvants in the antigen delivery system
Kalra et al. Virosomes: a viral envelope system having a promising application in vaccination and drug delivery system